Synthetic long peptides (SLP) for therapeutic vaccination against hepatitis B virus infection
AssigneeISA Pharmaceuticals B.V.
InventorsWilhelmus Johannes Theodorus Alexander Krebber, Johan Herman Kessler, Cornelis Joseph Maria Melief, Kitty Michelle Corinne Kwappenberg
Life of this patent
Estimating the term…
Abstract
The present invention relates to the fields of medicine and immunology. In particular, it relates to novel peptides that may be used in the treatment and/or prevention of a Hepatitis B viral infection and/or an Hepatitis B related disease or condition.
Claims25
An immunogenic pharmaceutical composition comprising:
- (a) a peptide of at least 30 and at most 40 amino acids in length and comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 51-79, 1142-1145 and 1468-1471,
- (b) an immune-stimulating amount of at least one pharmaceutically acceptable adjuvant selected from the group consisting of a human toll-like receptor ligand and/or agonist, Montanide ISA-51, Montanide ISA-720, dsRNA, cyclic dinucleotides (CDNs), Muramyl dipeptide (MDP), a tetanus toxin derived peptide, Interferon alpha (INFα), and combinations thereof.
An immunogenic pharmaceutical composition comprising:
- (a) a polynucleotide encoding a peptide at least 30 and at most 40 amino acids in length, wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 51-79, 1142-1145 and 1468-1471;
- (b) an immune-stimulating amount of at least one pharmaceutically acceptable adjuvant selected from the group consisting of a human toll-like receptor ligand and/or agonist, Montanide ISA-51, Montanide ISA-720, dsRNA, cyclic dinucleotides (CDNs), Muramyl dipeptide (MDP), a tetanus toxin derived peptide, Interferon alpha (IFNα), and combinations thereof.
An immunogenic pharmaceutical composition comprising a peptide of at least 30 and at most 40 amino acids in length and comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 51-79, 1142-1145 and 1468-1471, wherein the peptide further comprises a covalently linked functional group, an oligonucleotide conjugate, a sugar chain or glycan, or combinations thereof.
Dependencies are inferred from the claim text.